SCHEMBL831769

SCHEMBL831769

Cc1ccc2c(c1)c(-c1ccc[nH]c1=O)c(C(=O)NS(=O)(=O)C1CC1)n2Cc1cc(S(N)(=O)=O)ccc1F

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP2C8 P10632 1/20 0.39
AURKA O14965 1/20 0.34
TPX2 Q9ULW0 1/20 0.34
SCN9A Q15858 5/20 0.33
SCN5A Q14524 3/20 0.33
SCN2B O60939 3/20 0.33
SCN1B Q07699 3/20 0.33
SCN1A P35498 1/20 0.33
KMT2A Q03164 1/20 0.33
MOGAT2 Q3SYC2 3/20 0.32
CYP2C9 P11712 2/20 0.32
MGAT2 Q10469 1/20 0.32
PTGDR2 Q9Y5Y4 3/20 0.31
AKR1B1 P15121 1/20 0.31
CA1 P00915 1/20 0.31
CA2 P00918 1/20 0.31
PARG Q86W56 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL831189 0.94 CYP2C8 (0.39) CYP2C8AURKATPX2SCN9ASCN5A
SCHEMBL10256456 0.93 CYP2C8 (0.42) CYP2C8AURKATPX2SCN9ASCN5A
SCHEMBL831325 0.92 CYP2C8 (0.37) CYP2C8AURKATPX2SCN9ASCN5A
SCHEMBL831741 0.91 CYP2C8 (0.41) CYP2C8AURKATPX2SCN9ASCN5A
SCHEMBL832311 0.90 CYP2C8 (0.37) CYP2C8AURKATPX2SCN9ASCN5A
SCHEMBL831989 0.90 CYP2C8 (0.39) CYP2C8AURKATPX2SCN9ASCN5A
SCHEMBL831674 0.90 CYP2C8 (0.43) CYP2C8AURKATPX2SCN9ASCN5A
SCHEMBL831390 0.89 CYP2C8 (0.39) CYP2C8AURKATPX2SCN9ASCN5A
SCHEMBL13905361 0.89 CYP2C8 (0.38) CYP2C8AURKATPX2SCN9ASCN5A
SCHEMBL831226 0.88 CYP2C8 (0.40) CYP2C8KMT2APTGDR2AKR1B1CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143305-B2 2,3-substituted indole derivatives for treating viral infections SCHERING CORPORATION (US) 2012-03-27 US disclosed
US-8143305-B2 2,3-substituted indole derivatives for treating viral infections SCHERING CORPORATION (US) 2012-03-27 US disclosed
US-20110033417-A1 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS MERCK SHARP & DOHME CORP. 2011-02-10 US disclosed
US-20110033417-A1 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS MERCK SHARP & DOHME CORP. 2011-02-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110033417-A1 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS IDO2, IDO1, IRF3 CYP2C8 847/4885AURKA 1855/4885TPX2 1329/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.